IN2014CN00989A - - Google Patents
Info
- Publication number
- IN2014CN00989A IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
- Authority
- IN
- India
- Prior art keywords
- compounds
- treprostinil
- pah
- prodrugs
- covalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00989A true IN2014CN00989A (enExample) | 2015-04-10 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN989CHN2014 IN2014CN00989A (enExample) | 2011-08-12 | 2012-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (enExample) |
| EP (1) | EP2741781A1 (enExample) |
| JP (1) | JP6092867B2 (enExample) |
| KR (1) | KR101997939B1 (enExample) |
| CN (1) | CN103857413A (enExample) |
| AU (1) | AU2012296954B2 (enExample) |
| BR (1) | BR112014003225A2 (enExample) |
| CA (1) | CA2843883C (enExample) |
| HK (1) | HK1198359A1 (enExample) |
| IL (1) | IL230712A (enExample) |
| IN (1) | IN2014CN00989A (enExample) |
| MX (1) | MX349950B (enExample) |
| WO (1) | WO2013024052A1 (enExample) |
| ZA (1) | ZA201400977B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014003225A2 (pt) * | 2011-08-12 | 2017-03-01 | Ascendis Pharma As | profármacos de treprostinil ligados a veículo |
| EP2841109B1 (en) * | 2012-04-25 | 2026-04-15 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| EP2928501B1 (en) | 2012-12-07 | 2020-05-06 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (en) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| WO2014160638A1 (en) * | 2013-03-25 | 2014-10-02 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| CA2911172C (en) | 2013-04-30 | 2021-10-19 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| TWI685348B (zh) * | 2014-05-08 | 2020-02-21 | 美國禮來大藥廠 | 速效胰島素組合物 |
| ES2908142T3 (es) * | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| EP3169660A1 (en) * | 2014-07-16 | 2017-05-24 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| CA2967899C (en) | 2014-12-03 | 2023-09-19 | Steadymed Ltd | Preservative-free treprostinil formulations and methods and devices for use with same |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| JP6968802B2 (ja) | 2016-01-08 | 2021-11-17 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 環部分にキャリア結合を有するｃｎｐプロドラッグ |
| CA3008015A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability |
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| EP4710947A3 (en) | 2016-01-08 | 2026-06-17 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| KR102518217B1 (ko) | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
| SI3423103T1 (sl) | 2016-03-01 | 2024-12-31 | Ascendis Pharma Bone Diseases A/S | Predzdravila PTH |
| AU2017295938C1 (en) | 2016-07-13 | 2021-10-07 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| JP7527785B2 (ja) * | 2016-09-15 | 2024-08-05 | カムルス エービー | プロスタサイクリン類似体製剤 |
| HUE063235T2 (hu) | 2016-09-29 | 2024-01-28 | Ascendis Pharma Bone Diseases As | Adagolási rendszer szabályozott leadású PTH vegyülethez |
| KR102611820B1 (ko) | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
| RU2768747C2 (ru) | 2016-09-29 | 2022-03-24 | Асцендис Фарма Гроус Дизордерс А/С | Комбинаторная терапия с агонистами cnp контролируемого высвобождения |
| JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー／エス | 放出制御ｐｔｈ化合物の漸増用量設定 |
| EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| CA3099620A1 (en) | 2018-05-18 | 2019-11-21 | Ascendis Pharma Bone Diseases A/S | Starting dose of pth conjugates |
| EP3856256A1 (en) | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Novel hydrogel conjugates |
| CA3114056A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Treatment of infections |
| CA3114272A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| AU2020205029A1 (en) | 2019-01-04 | 2021-06-24 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
| SG11202105835YA (en) | 2019-01-04 | 2021-07-29 | Ascendis Pharma Oncology Div A/S | Conjugates of pattern recognition receptor agonists |
| SG11202104966XA (en) | 2019-01-04 | 2021-06-29 | Ascendis Pharma Oncology Div A/S | Sustained local drug levels for innate immune agonists |
| EP3906018A1 (en) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| AU2020221491B2 (en) | 2019-02-11 | 2025-02-27 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of PTH conjugates |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| CN119632930A (zh) | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| TW202114738A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 抗ctla4結合物 |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| CA3143278A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| JP2023510790A (ja) | 2020-01-13 | 2023-03-15 | アセンディス ファーマ ボーン ディジージズ エー／エス | 副甲状腺機能低下症の治療 |
| WO2021224169A1 (en) | 2020-05-04 | 2021-11-11 | Ascendis Pharma A/S | Hydrogel irradiation |
| AU2021289336B2 (en) * | 2020-06-09 | 2025-08-28 | Mannkind Corporation | Fumaryl diketopiperidine prodrugs of treprostinil |
| IL301411A (en) | 2020-09-28 | 2023-05-01 | Ascendis Pharma Bone Diseases As | Improvement of physical and mental well-being of patients with hypoparathyroidism |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| CN115025205A (zh) * | 2021-02-20 | 2022-09-09 | 四川海思科制药有限公司 | 一种肽酰胺类注射液药物组合物及其制备方法和用途 |
| CN117015524B (zh) * | 2021-03-16 | 2026-03-06 | 江苏恒瑞医药股份有限公司 | 一种曲前列环素衍生物及其用途 |
| AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| JP2024546134A (ja) | 2021-12-13 | 2024-12-17 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | Ｔｌｒ７／８アゴニストを用いたがん治療 |
| AU2022413318A1 (en) | 2021-12-13 | 2024-05-16 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| AU2023276829A1 (en) | 2022-05-23 | 2024-10-31 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| JP2025537527A (ja) | 2022-11-02 | 2025-11-18 | アセンディス ファーマ ボーン ディジージズ エー／エス | ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン |
| KR20250162619A (ko) | 2023-03-20 | 2025-11-18 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법 |
| EP4773987A1 (en) | 2023-09-04 | 2026-07-15 | Ascendis Pharma Bone Diseases A/S | Pth treatment of chronic kidney disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| KR20020012169A (ko) * | 1999-03-31 | 2002-02-15 | 유나이티드 쎄러퓨틱스 코포레이션 | 프로스타글란딘 화합물, 조성물 및 말초혈관질병 및폐고혈압증의 치료방법 |
| WO2004089280A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| US7199157B2 (en) * | 2003-12-16 | 2007-04-03 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
| CA2678258A1 (en) * | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| US8563521B2 (en) * | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| KR101671537B1 (ko) * | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | 다분지형 중합체 알카노에이트 컨쥬게이트 |
| EP2350118B1 (en) * | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| AU2009324637B2 (en) | 2008-12-10 | 2016-09-08 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| LT2459220T (lt) * | 2009-07-31 | 2020-12-28 | Ascendis Pharma A/S | Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu |
| US20130053405A1 (en) | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| BR112014003225A2 (pt) * | 2011-08-12 | 2017-03-01 | Ascendis Pharma As | profármacos de treprostinil ligados a veículo |
-
2012
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko not_active Expired - Fee Related
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 HK HK14111870.6A patent/HK1198359A1/xx unknown
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/en not_active Withdrawn
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en not_active Ceased
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1198359A1 (en) | 2015-04-10 |
| IL230712A (en) | 2017-08-31 |
| CN103857413A (zh) | 2014-06-11 |
| BR112014003225A2 (pt) | 2017-03-01 |
| AU2012296954B2 (en) | 2016-09-15 |
| WO2013024052A1 (en) | 2013-02-21 |
| KR20140070545A (ko) | 2014-06-10 |
| CA2843883C (en) | 2020-04-28 |
| CA2843883A1 (en) | 2013-02-21 |
| ZA201400977B (en) | 2017-11-29 |
| AU2012296954A1 (en) | 2014-02-20 |
| JP2014527050A (ja) | 2014-10-09 |
| MX349950B (es) | 2017-08-22 |
| MX2014001497A (es) | 2014-04-25 |
| US9561287B2 (en) | 2017-02-07 |
| EP2741781A1 (en) | 2014-06-18 |
| US10729778B2 (en) | 2020-08-04 |
| US20140296150A1 (en) | 2014-10-02 |
| US20190105400A1 (en) | 2019-04-11 |
| IL230712A0 (en) | 2014-03-31 |
| KR101997939B1 (ko) | 2019-07-08 |
| JP6092867B2 (ja) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349950B (es) | Profarmacos de treprostinil enlazados a un portador. | |
| PH12017501429A1 (en) | Derivatives of betulin | |
| MY187718A (en) | Pharmaceutical formulations | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX361653B (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| IN2012DN02139A (enExample) | ||
| MY153958A (en) | Lxr modulators | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| IN2014CN04449A (enExample) | ||
| WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
| IN2013DN02555A (enExample) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| WO2012176163A3 (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| MX2013002656A (es) | Nuevo proceso. |